Erythropoiesis-stimulating agents should have only a limited role in the treatment of anemia in cancer patients, according to updated clinical practice guidelines issued jointly by the American Society of Clinical Oncology and the American Society of Hematology.The guidelines committee recommends restricting the use of epoetin alfa (Epogen, Procrit) and darbepoetin (Aranesp) to patients who are undergoing myelosuppressive chemotherapy and have hemoglobin levels below 10 g/dL. In such cases, clinicians...